Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ZFGN - Zafgen Inc.

Previous close
0.99
0   0%

Share volume: 0
Last Updated: Thu 28 May 2020 06:00:00 AM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$0.99
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 37%
Dept financing 26%
Liquidity 31%
Performance 28%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.99
P/E Ratio 
N/A
DAY RANGE
$10.00 - $10.99
EPS 
-$0.96
52 WEEK RANGE
$0.62 - $2.76
52 WEEK CHANGE
-$58.58
MARKET CAP 
37.095 M
YIELD 
N/A
SHARES OUTSTANDING 
37.470 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$28,460,189
AVERAGE 10 VOLUME 
$1,660,930
AVERAGE 30 VOLUME 
$696,724
Company detail
CEO: Jeffrey S. Hatfield
Region: US
Website: http://www.zafgen.com
Employees: 7
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Recent news